标题
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 21, Issue 16, Pages 5820
出版商
MDPI AG
发表日期
2020-08-13
DOI
10.3390/ijms21165820
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens
- (2020) Juan Pablo Frias et al. DIABETES OBESITY & METABOLISM
- Dose‐dependent reduction in body weight with LIK066 treatment in Japanese patients with obesity
- (2020) Koutaro Yokote et al. DIABETES OBESITY & METABOLISM
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
- (2020) Lin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results
- (2020) K.J. Lucas et al. DIGESTIVE AND LIVER DISEASE
- Cilofexor, a Nonsteroidal FXR Agonist, in Non‐Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial
- (2020) Keyur Patel et al. HEPATOLOGY
- Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
- (2020) Eugene Han et al. Journal of Clinical Medicine
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- 1830-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice
- (2020) JAEHYUK CHOI et al. DIABETES
- Separate and Combined Gluco-Metabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 in Healthy Individuals
- (2019) Lærke S. Gasbjerg et al. DIABETES
- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- The Regulation of Peripheral Metabolism by Gut-Derived Hormones
- (2019) Emily W. L. Sun et al. Frontiers in Endocrinology
- Therapeutic FGF19 promotes HDL biogenesis and transhepatic cholesterol efflux to prevent atherosclerosis
- (2019) Mei Zhou et al. JOURNAL OF LIPID RESEARCH
- NGM 282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis
- (2019) Stephen A. Harrison et al. HEPATOLOGY
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes
- (2019) Yan‐Ling He et al. DIABETES OBESITY & METABOLISM
- FGF19 Analogue as a Surgical Factor Mimetic that Contributes to Metabolic Effects Beyond Glucose Homeostasis
- (2019) Alex M. DePaoli et al. DIABETES
- Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
- (2019) Satoshi Ida et al. Cardiovascular Diabetology
- Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies
- (2019) Jie Liu et al. Diabetes & Vascular Disease Research
- PS-110-Ketohexokinase inhibitor PF-06835919 administered for 6 weeks reduces whole liver fat as measured by magnetic resonance imaging-proton density fat fraction in subjects with non-alcoholic fatty liver disease
- (2019) Roberto Calle et al. JOURNAL OF HEPATOLOGY
- LBP-29-BIO89-100, a novel PEG-FGF21 analogue, is efficacious following weekly and every 2-week subcutaneous dosing in spontaneous diabetic cynomolgus monkeys
- (2019) Moti Rosenstock et al. JOURNAL OF HEPATOLOGY
- PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects
- (2019) Alex DePaoli et al. JOURNAL OF HEPATOLOGY
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- New dual peroxisome proliferator activated receptor agonist—Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence
- (2019) Upendra Kaul et al. Cardiovascular Diabetology
- 982-P: A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects
- (2019) JAE DUK CHOI et al. DIABETES
- 140-LB: NGM313, a Novel Activator of b-Klotho/FGFR1c, Improves Insulin Resistance and Reduces Hepatic Fat in Obese, Nondiabetic Subjects
- (2019) ALEX DEPAOLI et al. DIABETES
- The incretin system in healthy humans: The role of GIP and GLP-1
- (2019) Jens Juul Holst METABOLISM-CLINICAL AND EXPERIMENTAL
- Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
- (2019) Clara Depommier et al. NATURE MEDICINE
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development
- (2019) Juliette Mouries et al. JOURNAL OF HEPATOLOGY
- First‐in‐class fatty acid synthase inhibitor TVB‐2640 reduces hepatic de novo lipogenesis in males with metabolic abnormalities
- (2019) Majid M. Syed‐Abdul et al. HEPATOLOGY
- Efficacy, safety, and mechanistic insights of cotadutide a dual receptor glucagon-like peptide-1 and glucagon agonist
- (2019) Victoria E R Parker et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study
- (2019) Stephen A. Harrison et al. JOURNAL OF HEPATOLOGY
- Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2019) Stephen A Harrison et al. LANCET
- Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
- (2019) Amalia Gastaldelli et al. DIABETES OBESITY & METABOLISM
- Increased liver localization of lipopolysaccharides in human and experimental non‐alcoholic fatty liver disease
- (2019) Guido Carpino et al. HEPATOLOGY
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
- (2019) Zobair M Younossi et al. LANCET
- Marked differences in tight junction composition and macromolecular permeability among different intestinal cell types
- (2018) Sarah C. Pearce et al. BMC BIOLOGY
- SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice
- (2018) Dustin M. Lee et al. Cardiovascular Diabetology
- Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis
- (2018) Eric J. Lawitz et al. Clinical Gastroenterology and Hepatology
- Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
- (2018) Fernando Bril et al. Clinical Gastroenterology and Hepatology
- Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in a NASH and Fibrosis Animal Model
- (2018) IN YOUNG CHOI et al. DIABETES
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis
- (2018) Jerry R. Colca et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Human gut microbiome: hopes, threats and promises
- (2018) Patrice D Cani GUT
- Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort
- (2018) Jasmohan S. Bajaj et al. HEPATOLOGY
- Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease
- (2018) Francesca Romana Ponziani et al. HEPATOLOGY
- Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism
- (2018) Preeti Pathak et al. HEPATOLOGY
- Lipotoxicity and the gut-liver axis in NASH pathogenesis
- (2018) Fabio Marra et al. JOURNAL OF HEPATOLOGY
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
- (2018) Benaïssa Boubia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials
- (2018) Boyu Li et al. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES
- NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
- (2018) Stephen A Harrison et al. LANCET
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women
- (2018) Lesley Hoyles et al. NATURE MEDICINE
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
- (2018) Christophe Corpechot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut hormone polyagonists for the treatment of type 2 diabetes
- (2018) Sara J. Brandt et al. PEPTIDES
- Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection
- (2018) Christoph A. Thaiss et al. SCIENCE
- Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review
- (2018) Katia P. Souto et al. Surgery for Obesity and Related Diseases
- Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
- (2018) Paul Chi Ho Lee et al. Diabetes Therapy
- Dapagliflozin and Empagliflozin Ameliorate Hepatic Dysfunction Among Chinese Subjects with Diabetes in Part Through Glycemic Improvement: A Single-Center, Retrospective, Observational Study
- (2018) Paul Chi Ho Lee et al. Diabetes Therapy
- Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT
- (2018) Jotham Suez et al. CELL
- A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
- (2018) Joachim Tillner et al. DIABETES OBESITY & METABOLISM
- Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomized controlled study
- (2018) Niina Matikainen et al. DIABETES OBESITY & METABOLISM
- Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease
- (2018) Huikuan Chu et al. GUT
- Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
- (2018) Zobair Younossi et al. HEPATOLOGY
- Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
- (2018) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Lixisenatide reduces chylomicron triacylglycerol due to increased clearance
- (2018) Martin B Whyte et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Peptide-based multi-agonists: a new paradigm in metabolic pharmacology
- (2018) Sara J. Brandt et al. JOURNAL OF INTERNAL MEDICINE
- Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction
- (2018) Chunwei Cheng et al. LIFE SCIENCES
- The Potential Role of the Dipeptidyl Peptidase-4-Like Activity From the Gut Microbiota on the Host Health
- (2018) Marta Olivares et al. Frontiers in Microbiology
- Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
- (2018) Teruki Miyake et al. Open Medicine
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
- (2018) Mary E. Rinella et al. JOURNAL OF HEPATOLOGY
- Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial
- (2018) Gideon M. Hirschfield et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
- (2018) Marta Seghieri et al. Frontiers in Endocrinology
- Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
- (2018) Yuya Seko et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease
- (2017) Malek Yaghoubi et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats
- (2017) Qian Zhang et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
- (2017) Akio Ohta et al. EXPERT OPINION ON PHARMACOTHERAPY
- New therapeutic concepts in bile acid transport and signaling for management of cholestasis
- (2017) Michael Trauner et al. HEPATOLOGY
- A novel glucagon-like peptide 1/glucagon receptor dual agonist improves steatohepatitis and liver regeneration in mice
- (2017) M. Pilar Valdecantos et al. HEPATOLOGY
- The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids
- (2017) Puneet Puri et al. HEPATOLOGY
- Exploring the therapeutic potential of Glucagon/GLP-1 dual agonist ZP2929 in a mouse model of diet induced and biopsy-confirmed non-alcoholic steatohepatitis
- (2017) J. Skarbaliene et al. JOURNAL OF HEPATOLOGY
- Mouse species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15
- (2017) Mei Zhou et al. JOURNAL OF HEPATOLOGY
- NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
- (2017) Auvro R. Mridha et al. JOURNAL OF HEPATOLOGY
- Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness
- (2017) Yong-ho Lee et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
- (2017) David C. Tully et al. JOURNAL OF MEDICINAL CHEMISTRY
- Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis
- (2017) Wei Jia et al. Nature Reviews Gastroenterology & Hepatology
- Pancreas and liver uptake of new radiolabeled incretins (GLP-1 and Exendin-4) in models of diet-induced and diet-restricted obesity
- (2017) Daniele Seo et al. NUCLEAR MEDICINE AND BIOLOGY
- Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats
- (2017) Qian Zhang et al. PLoS One
- The Human Gut Microbiome in Liver Diseases
- (2017) Brian Davis et al. SEMINARS IN LIVER DISEASE
- Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
- (2017) Giovanna Muscogiuri et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial
- (2017) Tisha R Joy et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Gastric acid suppression promotes alcoholic liver disease by inducing overgrowth of intestinal Enterococcus
- (2017) Cristina Llorente et al. Nature Communications
- Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis
- (2017) Mei Zhou et al. Nature Communications
- Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis
- (2017) Yajie Dong et al. Clinics and Research in Hepatology and Gastroenterology
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
- (2017) Sigrid Jall et al. Molecular Metabolism
- Metformin Improves Ileal Epithelial Barrier Function in Interleukin-10 Deficient Mice
- (2017) Yansong Xue et al. PLoS One
- Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
- (2017) Irene Pierantonelli et al. Scientific Reports
- Metformin exerts glucose-lowering action in high-fat fed mice via attenuating endotoxemia and enhancing insulin signaling
- (2016) Zi-yu Zhou et al. ACTA PHARMACOLOGICA SINICA
- Gut permeability is related to body weight, fatty liver disease, and insulin resistance in obese individuals undergoing weight reduction
- (2016) Antje Damms-Machado et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats
- (2016) Jin-Hang Gao et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
- (2016) Kenneth Cusi et al. ANNALS OF INTERNAL MEDICINE
- Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
- (2016) Takamasa Ohki et al. CLINICAL DRUG INVESTIGATION
- Clinical Diabetes/Therapeutics
- (2016) DIABETES
- Effect of canagliflozin on liver function tests in patients with type 2 diabetes
- (2016) L.A. Leiter et al. DIABETES & METABOLISM
- Metformin Is Associated With Higher Relative Abundance of Mucin-DegradingAkkermansia muciniphilaand Several Short-Chain Fatty Acid–Producing Microbiota in the Gut
- (2016) Jacobo de la Cuesta-Zuluaga et al. DIABETES CARE
- Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
- (2016) S. J. Henderson et al. DIABETES OBESITY & METABOLISM
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3–36
- (2016) Eva W Iepsen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity
- (2016) Pierre Bedossa et al. GUT
- Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
- (2016) Amalia Gastaldelli et al. HEPATOLOGY
- Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives
- (2016) Juan P. Arab et al. HEPATOLOGY
- Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach
- (2016) Federica Del Chierico et al. HEPATOLOGY
- The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota
- (2016) Jérôme Boursier et al. HEPATOLOGY
- Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis
- (2016) Guoxiang Xie et al. INTERNATIONAL JOURNAL OF CANCER
- Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
- (2016) Jean-Michel Petit et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Intra-islet glucagon-like peptide 1
- (2016) Genevieve E. Fava et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial
- (2016) Jeffrey Cui et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice
- (2016) Hubert Plovier et al. NATURE MEDICINE
- The role of the gut microbiota in NAFLD
- (2016) Christopher Leung et al. Nature Reviews Gastroenterology & Hepatology
- Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease
- (2016) Claudia Fuchs et al. SEMINARS IN LIVER DISEASE
- Distinctly altered gut microbiota in the progression of liver disease
- (2016) Guoxiang Xie et al. Oncotarget
- Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study
- (2016) Xinfeng Yan et al. Journal of Diabetes Research
- The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- Non-alcoholic fatty liver and the gut microbiota
- (2016) Stavros Bashiardes et al. Molecular Metabolism
- Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
- (2015) Giuseppe Daniele et al. DIABETES
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Bile Acids as Hormones: The FXR-FGF15/19 Pathway
- (2015) Steven A. Kliewer et al. DIGESTIVE DISEASES
- Akkermansia muciniphilaand improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology
- (2015) Maria Carlota Dao et al. GUT
- Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease
- (2015) Norelle R. Reilly et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance
- (2015) Sungsoon Fang et al. NATURE MEDICINE
- Gut biogeography of the bacterial microbiota
- (2015) Gregory P. Donaldson et al. NATURE REVIEWS MICROBIOLOGY
- Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
- (2015) Changtao Jiang et al. Nature Communications
- How Inflammation Impinges on NAFLD: A Role for Kupffer Cells
- (2015) Nádia Duarte et al. Biomed Research International
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes
- (2014) Yan Bi et al. ACTA DIABETOLOGICA
- Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
- (2014) Hui Fan et al. Arquivos Brasileiros de Endocrinologia e Metabologia
- Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19
- (2014) M. Zhou et al. CANCER RESEARCH
- The Fatty Acid–Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease
- (2014) Rifaat Safadi et al. Clinical Gastroenterology and Hepatology
- Can a Selective PPARγ Modulator Improve Glycemic Control in Patients With Type 2 Diabetes With Fewer Side Effects Compared With Pioglitazone?
- (2014) Alex M. DePaoli et al. DIABETES CARE
- Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes
- (2014) T. Heise et al. DIABETES OBESITY & METABOLISM
- Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
- (2014) Ning Shao et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity
- (2014) Valentina Giorgio et al. DIGESTIVE AND LIVER DISEASE
- GLP-1 Receptor Localization in Monkey and Human Tissue: Novel Distribution Revealed With Extensively Validated Monoclonal Antibody
- (2014) Charles Pyke et al. ENDOCRINOLOGY
- Prevention of spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice by intestinal-specific farnesoid X receptor reactivation
- (2014) Chiara Degirolamo et al. HEPATOLOGY
- Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
- (2014) Yuichiro Eguchi et al. HEPATOLOGY RESEARCH
- Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
- (2014) Changtao Jiang et al. JOURNAL OF CLINICAL INVESTIGATION
- NLRP3 inflammasome activation is required for fibrosis development in NAFLD
- (2014) Alexander Wree et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH
- (2014) Samuele De Minicis et al. PLoS One
- Regionally Distinct Alterations in the Composition of the Gut Microbiota in Rats with Streptozotocin-Induced Diabetes
- (2014) Roland Wirth et al. PLoS One
- Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity
- (2014) Sophie Leclercq et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease
- (2014) Kouichi Miura WORLD JOURNAL OF GASTROENTEROLOGY
- Effects of sitagliptin on ectopic fat contents and glucose metabolism in type 2 diabetic patients with fatty liver: A pilot study
- (2014) Takahiro Watanabe et al. Journal of Diabetes Investigation
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial
- (2014) Norbert Stefan et al. Lancet Diabetes & Endocrinology
- Role of Innate Immune Response in Non-Alcoholic Fatty Liver Disease: Metabolic Complications and Therapeutic Tools
- (2014) Rosaria Meli et al. Frontiers in Immunology
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- GLP-1/Glucagon Coagonism Restores Leptin Responsiveness in Obese Mice Chronically Maintained on an Obesogenic Diet
- (2013) C. Clemmensen et al. DIABETES
- Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial
- (2013) K. Hermansen et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2013) Sunder Mudaliar et al. GASTROENTEROLOGY
- Intestinal microbiota in patients with nonalcoholic fatty liver disease
- (2013) Marialena Mouzaki et al. HEPATOLOGY
- Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice
- (2013) Samuele De Minicis et al. HEPATOLOGY
- Effects of Liraglutide, a Human Glucagon-like Peptide-1 Analogue, on Body Weight, Body Fat Area and Body Fat-related Markers in Patients with Type 2 Diabetes Mellitus
- (2013) Daisuke Suzuki et al. INTERNAL MEDICINE
- The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism
- (2013) Gijs den Besten et al. JOURNAL OF LIPID RESEARCH
- GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK
- (2013) Lili Zhang et al. LIVER INTERNATIONAL
- Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome
- (2013) Shin Yoshimoto et al. NATURE
- Diet rapidly and reproducibly alters the human gut microbiome
- (2013) Lawrence A. David et al. NATURE
- The gut microbiota — masters of host development and physiology
- (2013) Felix Sommer et al. NATURE REVIEWS MICROBIOLOGY
- Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials
- (2013) Michael Grimm et al. POSTGRADUATE MEDICINE
- Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients
- (2013) Kristina Blaslov et al. Clinics and Research in Hepatology and Gastroenterology
- Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program
- (2012) M. J. Armstrong et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The Glucagon-Like Peptide-1 Receptor Agonist Exendin 4 Has a Protective Role in Ischemic Injury of Lean and Steatotic Liver by Inhibiting Cell Death and Stimulating Lipolysis
- (2012) Nitika A. Gupta et al. AMERICAN JOURNAL OF PATHOLOGY
- Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice
- (2012) James L. Trevaskis et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
- (2012) Jonathan W. Day et al. BIOPOLYMERS
- Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
- (2012) Seiki Miura et al. BMC CANCER
- Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
- (2012) Dianne H. Dapito et al. CANCER CELL
- Intestinal Permeability and Its Regulation by Zonulin: Diagnostic and Therapeutic Implications
- (2012) Alessio Fasano Clinical Gastroenterology and Hepatology
- Exenatide once weekly improved glycaemic control, cardiometabolic risk factors and a composite index of an HbA1c < 7%, without weight gain or hypoglycaemia, over 52 weeks
- (2012) R. M. Bergenstal et al. DIABETES OBESITY & METABOLISM
- Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
- (2012) M. Nauck et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes
- (2012) Y.-S. Lee et al. DIABETOLOGIA
- Direct effect of GLP-1 infusion on endogenous glucose production in humans
- (2012) M. Seghieri et al. DIABETOLOGIA
- Nutrition, Intestinal Permeability, and Blood Ethanol Levels Are Altered in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
- (2012) Valentina Volynets et al. DIGESTIVE DISEASES AND SCIENCES
- Transfer of Intestinal Microbiota From Lean Donors Increases Insulin Sensitivity in Individuals With Metabolic Syndrome
- (2012) Anne Vrieze et al. GASTROENTEROLOGY
- Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH
- (2012) Lixin Zhu et al. HEPATOLOGY
- Toxic lipids stored by Kupffer cells correlates with their pro-inflammatory phenotype at an early stage of steatohepatitis
- (2012) Anne Leroux et al. JOURNAL OF HEPATOLOGY
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
- (2012) Jorge Henao-Mejia et al. NATURE
- The role of the gut microbiota in nutrition and health
- (2012) Harry J. Flint et al. Nature Reviews Gastroenterology & Hepatology
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
- (2012) Edwin T. Parlevliet et al. PLoS One
- Host-Gut Microbiota Metabolic Interactions
- (2012) J. K. Nicholson et al. SCIENCE
- The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone
- (2012) Takamasa Ohki et al. TheScientificWorldJOURNAL
- Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice
- (2011) Timea Csak et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Diet-Induced Adipose Tissue Inflammation and Liver Steatosis Are Prevented by DPP-4 Inhibition in Diabetic Mice
- (2011) J. Shirakawa et al. DIABETES
- Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2
- (2011) G. Tolhurst et al. DIABETES
- Effects of Exenatide on Measures of -Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
- (2011) M. C. Bunck et al. DIABETES CARE
- Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
- (2011) S. L. Samson et al. DIABETOLOGIA
- Host Response to Translocated Microbial Products Predicts Outcomes of Patients With HBV or HCV Infection
- (2011) Netanya G. Sandler et al. GASTROENTEROLOGY
- Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects
- (2011) E. Cersosimo et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Lipotoxicity in NASH
- (2011) Michael Fuchs et al. JOURNAL OF HEPATOLOGY
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
- Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism
- (2011) Masayuki Miyazaki Molecular Medicine Reports
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
- (2011) Bolormaa Vandanmagsar et al. NATURE MEDICINE
- Effects of Combined Exenatide and Pioglitazone Therapy on Hepatic Fat Content in Type 2 Diabetes
- (2011) Padma Sathyanarayana et al. Obesity
- GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
- (2011) Shvetank Sharma et al. PLoS One
- Inflammasome is a central player in the induction of obesity and insulin resistance
- (2011) R. Stienstra et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Exenatide in the Treatment of Diabetic Patients With Non-Alcoholic Steatohepatitis: A Case Series
- (2010) Patrick R Kenny et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
- (2010) Eric A. Schwartz et al. ATHEROSCLEROSIS
- Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
- (2010) M. Asmar et al. DIABETES
- Effects of Exenatide Plus Rosiglitazone on -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
- (2010) R. A. DeFronzo et al. DIABETES CARE
- Molecular mechanisms underlying nutrient-stimulated incretin secretion
- (2010) Helen E. Parker et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Toll-Like Receptor 9 Promotes Steatohepatitis by Induction of Interleukin-1β in Mice
- (2010) Kouichi Miura et al. GASTROENTEROLOGY
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents
- (2010) Le-Xing Yu et al. HEPATOLOGY
- Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
- (2010) Herbert Tilg et al. HEPATOLOGY
- The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental Colitis
- (2010) Md. Hasan Zaki et al. IMMUNITY
- Fenofibrate Reduces Systemic Inflammation Markers Independent of Its Effects on Lipid and Glucose Metabolism in Patients with the Metabolic Syndrome
- (2010) Renata Belfort et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
- (2010) Shani Ben-Shlomo et al. JOURNAL OF HEPATOLOGY
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
- (2010) Clifford J Bailey et al. LANCET
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
- (2010) Arun J. Sanyal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker
- (2010) Gábor Firneisz et al. PLoS One
- Farnesoid X Receptor Critically Determines the Fibrotic Response in Mice but Is Expressed to a Low Extent in Human Hepatic Stellate Cells and Periductal Myofibroblasts
- (2009) Peter Fickert et al. AMERICAN JOURNAL OF PATHOLOGY
- Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
- (2009) A. Pocai et al. DIABETES
- Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue
- (2009) J. Jendle et al. DIABETES OBESITY & METABOLISM
- Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
- (2009) Luca Miele et al. HEPATOLOGY
- Comparable effects of moderate intensity exercise on changes in anorectic gut hormone levels and energy intake to high intensity exercise
- (2009) Shin-ya Ueda et al. JOURNAL OF ENDOCRINOLOGY
- Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic Acid (MK-0533): A Novel Selective Peroxisome Proliferator-Activated Receptor γ Modulator for the Treatment of Type 2 Diabetes Mellitus with a Reduced Potential to Increase Plasma and Extracellular Fluid Volume
- (2009) John J. Acton et al. JOURNAL OF MEDICINAL CHEMISTRY
- A new glucagon and GLP-1 co-agonist eliminates obesity in rodents
- (2009) Jonathan W Day et al. Nature Chemical Biology
- Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog
- (2009) K. Machida et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study
- (2008) Ralph A. DeFronzo et al. CURRENT MEDICAL RESEARCH AND OPINION
- Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice
- (2008) P. D. Cani et al. DIABETES
- A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease
- (2008) C. Fernández-Miranda et al. DIGESTIVE AND LIVER DISEASE
- Microbes in Gastrointestinal Health and Disease
- (2008) Andrew S. Neish GASTROENTEROLOGY
- Gene Therapy for Diabetes: Metabolic Effects of Helper-dependent Adenoviral Exendin 4 Expression in a Diet-induced Obesity Mouse Model
- (2008) Susan L Samson et al. MOLECULAR THERAPY
- Targeting bile-acid signalling for metabolic diseases
- (2008) Charles Thomas et al. NATURE REVIEWS DRUG DISCOVERY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started